Floatz logo

Orforglipron

Chronic Kidney Disease

Eli Lilly and CompanySmall moleculePhase 3Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

29 Active assets in the Chronic Kidney Disease cohort.

Asset / SponsorPhaseRating
SODIUM FERRIC GLUCONATE
Watson Pharmaceuticals
Phase 4BBB
IRON(II) SULPHATE (1:1), HEPTAHYDRATE
Watson Pharmaceuticals
Phase 4BBB
Semaglutide
Institute of Liver and Biliary Sciences, India
Phase 4BBB
Plavix
Hospital Alemão Oswaldo Cruz
Phase 4BB
Acetylsalicylic Acid
Hospital Alemão Oswaldo Cruz
Phase 4BB

View all 50 →

Same molecule, other indications

Orforglipron is also rated in:

obesity disorderDormant
BB
Indicative ·
68 / 100
View asset →
obesity disorderDormant
BB
Indicative ·
66 / 100
View asset →
atherosclerotic cardiovascular diseaseDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →